| HRA005098
(Controlled Access)
|
This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with cetuximab plus irinotecan for patients with relapsed or refractory colorectal cancer with RAS wild-type. Patients with RAS wild-type colorectal cancer who had failed at least 2 prior lines of systematic therapy including chemotherapy (oxaliplatin, irinotecan, fluoropyrimidines) with or without targeted agents (cetuximab, bevacizumab) will be recruited in this study. NGS and immune-related proteins test in blood samples obtained before treatment, 4 weeks after the first administration, first assessment at 8 weeks, and at progression aim to assess exploratory predictive biomarkers. |
